Is AstraZeneca plc a strong buy after Q3 results?

Is AstraZeneca plc (LON: AZN) still on course for a recovery?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The last few years have been incredibly challenging for AstraZeneca (LSE: AZN). The company has suffered major falls in its earnings due to the loss of patents on key drugs. Generic competition has caused its earnings per share to drop by 37% between 2012 and 2016, with further falls expected in the current financial year.

However, following investment in its pipeline in recent years, investors have become increasingly optimistic about its prospects. After a third quarter update on Thursday, is there still cause for optimism regarding the company’s future?

Improving performance

Encouragingly, AstraZeneca has reported that the impact from the loss of exclusivity on its products is starting to recede. Sales in the quarter declined by just 2% at constant currency, and this shows that its strategy is working as planned. Alongside investment in its pipeline, there have been major cost cuts which continue to lessen the impact of the sales decline on its bottom line. For example, research and development costs moved 1% lower at constant currency, while its operating costs moved 11% lower.

Should you invest £1,000 in BT right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if BT made the list?

See the 6 stocks

The result of this performance is expected to be a core earnings per share figure for the full year which is at the favourable end of guidance. This means that a low-teens percentage fall in earnings is on the cards for this year, which may help to boost investor sentiment in the short run.

Improving outlook

As mentioned, the company is investing heavily in its product pipeline. This has only been possible because of the strong balance sheet and cash flow of the business, and it is set to deliver positive earnings growth next year. While a rise of just 1% may be forecast for 2018, more earnings growth could be ahead as the impact of a loss of patents continues to recede and it is replaced with strong growth in the areas of the business in which it has invested in prior years.

With an improving outlook, it is perhaps unsurprising that AstraZeneca trades on a price-to-earnings (P/E) ratio of 17.8. This appears to be fair value for a company which has the potential to increase its profitability at a brisk pace in future. Furthermore, at its current price level it has a dividend yield of 4.2% from a shareholder payout which is covered 1.3 times by profit. This suggests that its income prospects are also bright.

Investment potential

As well as its capital growth and income prospects, AstraZeneca also has defensive appeal. It is less highly correlated to the performance of the wider economy than many of its FTSE 100 index peers. This could provide its investors with greater stability and resilience than they may be able to obtain in most stocks. As such, with its third quarter results showing continued improvements in its financial performance, now could be the right time to buy it for the long run.

Should you invest £1,000 in BT right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets.

And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if BT made the list?

See the 6 stocks

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares in AstraZeneca. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young Black woman looking concerned while in front of her laptop
Investing Articles

Are Tesco shares a screaming buy after sinking to 9-month lows?

Tesco shares continue to experience price weakness as signs of mounting competition grow. But is it now too cheap to…

Read more »

Investing Articles

Down 31%! 1 top growth stock to consider at $10 for a Stocks and Shares ISA

This high-quality stock has pulled back sharply since November, making it a possible candidate for a growth-oriented Stocks and Shares…

Read more »

Long-term vs short-term investing concept on a staircase
Investing Articles

Down 28% in 8 months, is AstraZeneca’s share price too cheap for me to pass up right now?

AstraZeneca’s share price has fallen a long way from its September high, but this may mean an opportunity for me…

Read more »

Investing Articles

Is April a great time to start investing?

Our writer spotlights a top-tier tech stock that has sold off recently, making it worthy of consideration for someone ready…

Read more »

Investing Articles

1 beaten down dividend stock investors could consider for passive income

Our writer Ken Hall takes a look at one under-pressure mining giant that should be on investors' radars as a…

Read more »

Affectionate Asian senior mother and daughter using smartphone together at home, smiling joyfully
Investing Articles

3 FTSE 100 investment trusts to consider for a new ISA in 2025

It's a new tax year and time to dust off that old ISA. Here are three FTSE 100 investment trusts…

Read more »

Young woman working at modern office. Technical price graph and indicator, red and green candlestick chart and stock trading computer screen background.
Investing Articles

Is there still time to pick up Nvidia stock cheaply?

The Nvidia stock price has just had a scary week. But here's why I expect that should have very little…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

Investors considering Legal & General shares could aim for £10,075 a year in passive income from a £5,500 stake!

Legal & General shares deliver one of the highest yields of any major FTSE-listed firm, so investing now could generate…

Read more »